Get started
Work

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

Year: 2020
Type: article
Abstract: We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by genotype-guided tamoxifen dosing in patients with intermediate CYP2D6 metabolism.
DOI: 10.17615/50yq-ck14
Authors: Weck, Karen E., Anderson, Steven M., Ogburn, Evan T., Flockhart, David A., Friedman, Kenneth J., McLeod, Howard L., Desta, Zeruesenay, Ibrahim, Joseph G., Walko, Christine M., Irvin, William J., Canale, Sean T., Corso, Steven W., Carey, Lisa A., Moore, Susan G., Olajide, Oludamilola A., Graham, Mark L., Raab, Rachel E., Dees, E. Claire, Evans, James P., Chiu, Wing K., Peppercorn, Jeffrey M.
Language: English
Subfield: Pharmacology
Open Access status: green
Funders: Breast Cancer Research Foundation, Pfizer, Myriad Genetics, University of North Carolina at Chapel Hill, National Cancer Institute, National Institute of General Medical Sciences
OpenAlex ID: W4298298484
FWCI:
Cites:
Cited by:
Related to: 10